Datapoint: Heron Sees Rocky Zynrelef Launch

Heron Therapeutics’ opioid alternative Zynrelef is not seeing the blockbuster launch some analysts predicted. Commercially launched in July 2021, Zynrelef’s fourth-quarter 2021 sales were just $0.8 million, according to a Feb. 28 earnings release. The drug is currently approved to treat postoperative pain in adult patients following total knee replacement, bunionectomy and groin hernia repair. Under the pharmacy benefit, just 8% of all insured lives have covered or better access to Zynrelef.

SOURCE: MMIT Analytics, as of 3/7/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 29

Datapoint: Nebraska Awards Medicaid Contracts

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: Lilly Scores Sweeping Label Expansion for Retevmo

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: Judge Says United Can Complete Change Healthcare Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today